Skip to Content
 

VICC toll-free number 1-877-936-8422

Lung and Thoracic Cancers

Clinical Trials for Lung Cancers

38 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Melanoma
Non Small Cell

VICCMEL15137

07/21/2015

Characterizing the Cardiometabolic Implications of Immune Therapy

Basic Science

Lung
Non Small Cell
Small Cell

VICCTHO0398

12/04/2003

Molecular Predictors of Lung Cancer Behavior. (SPORE)

Basic Science

Lung
Non Small Cell

VICCTHO0136

05/01/2001

Molecular Fingerprinting of Lung Cancer (SPORE)

Other

Lung

VICCTHO15123

05/20/2016

The PERCEPTA Registry

Other

Lung
Non Small Cell

ECOGTHOA151216

09/17/2015

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Other

Lung
Miscellaneous
Small Cell

VICCMD1494

10/31/2014

Specimen Collection under Clinical Protocol 06-C-0213 for Generation of Patient-Derived Models

Supportive Care

Lung

VICCTHO1657

10/14/2016

A Pivotal Multi-Center, Randomized, Controlled, Single-Blinded Study Comparing the Silver Nitrate-Coated Indwelling Pleural Catheter (SNCIPC) to the Uncoated PleurX? Pleural Catheter for the Management of Symptomatic, Recurrent, Malignant Pleural Effusions

Treatment

Lung
Non Small Cell

VICCTHO16148

05/25/2017

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment

Lung

VICCTHO1691

04/25/2017

A Phase II Single-Arm Trial to Investigate Tepotinib in advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-Doublet-Containing Regimen

Treatment

Bladder
Breast
Colon
Gastric/Gastroesophageal
Head/Neck
Liver
Lung
Melanoma
Non Small Cell
Ovarian
Pancreatic
Rectal
Sarcoma

VICCMD1605

03/28/2017

Phase 1/2a Study of Double-Immune Suppression Blockade by Combining a CSF1R Inhibitor (PLX3397) with an Anti-PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors

Treatment

Head/Neck
Lung
Melanoma
Non Small Cell

VICCMD1636

12/21/2016

A Phase 1b/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

Treatment

Lung
Melanoma
Non Small Cell

VICCMD1649

12/14/2016

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma

Treatment

Lung
Neuroendocrine

VICCTHO15115

11/08/2016

A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120 Mg Plus Bsc Vs. Placebo Plus Bsc For Tumor Control In Subjects With Well Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Ovarian
Uterine

VICCPHI1676

11/04/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Lung
Small Cell

NRGTHOCC003

10/24/2016

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Treatment

Gastric/Gastroesophageal
Liver
Lung

VICCPHI15114

09/28/2016

An Open-Label, Multicenter, Phase 1 study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Uterine

VICCPHI1634

08/30/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Lung
Non Small Cell

VICCTHO1614

08/05/2016

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

Treatment

Hematologic
Leukemia
Lung
Miscellaneous
Small Cell

VICCHEMP1615

07/21/2016

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects with Advanced Malignancies

Treatment

Lung

VICCTHO15129

06/07/2016

XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Treatment

Lung
Small Cell

VICCTHO15117

05/19/2016

A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Carcinoma (TRINITY)

Treatment

Colon
Head/Neck
Liver
Lung
Miscellaneous
Neuro-Oncology
Rectal
Sarcoma
Thyroid

VICCMD15110

04/05/2016

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Treatment

Colon
Head/Neck
Lung
Lymphoma
Melanoma
Non Small Cell
Ovarian
Rectal

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

Bladder
Breast
Colon
Esophageal
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Lung
Melanoma
Non Small Cell
Pancreatic
Rectal
Urologic
Uterine

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

Lung

VICCTHO1519

10/07/2015

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti−PDL1 Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine For PD L1-Selected Chemotherapy-Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

ECOGTHOE4512

09/15/2015

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment

Lung
Small Cell

VICCTHO1510

07/09/2015

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

ECOGTHOS1400

04/02/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung

CTSUTHOS1400

01/20/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Lung-MAP Study Targeted Treatment for Advanced Squamous Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Treatment

Lung

ECOGTHO2511-M

11/04/2014

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Treatment

Lung

THOMK3475-024-M

08/05/2014

MK3475-024 A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHN1244

07/25/2012

Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer

Treatment

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

Lung

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

Treatment

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Treatment

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)